Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis

[1]  E. Crouser,et al.  Challenges of Sarcoidosis and Its Management. , 2021, The New England journal of medicine.

[2]  A. Flanagin,et al.  Updated Guidance on the Reporting of Race and Ethnicity in Medical and Science Journals. , 2021, JAMA.

[3]  C. Ko,et al.  Cytokine RNA In Situ Hybridization Permits Individualized Molecular Phenotyping in Biopsies of Psoriasis and Atopic Dermatitis , 2021, JID innovations.

[4]  N. Aghaeepour,et al.  High-dimensional profiling clusters asthma severity by lymphoid and non-lymphoid status , 2021, Cell reports.

[5]  Ivana V. Yang,et al.  Single-cell RNA sequencing identifies macrophage transcriptional heterogeneities in granulomatous diseases , 2021, European Respiratory Journal.

[6]  M. Bottai,et al.  Monocytes in sarcoidosis are potent tumour necrosis factor producers and predict disease outcome , 2021, European Respiratory Journal.

[7]  M. Becich,et al.  Transcriptomics of bronchoalveolar lavage cells identifies new molecular endotypes of sarcoidosis , 2020, European Respiratory Journal.

[8]  S. Arron,et al.  Single cell RNA-seq of psoriatic skin identifies pathogenic Tc17 subsets and reveals distinctions between CD8+ T cells in autoimmunity and cancer. , 2020, The Journal of allergy and clinical immunology.

[9]  M. Murphy,et al.  Paradoxical eruptions to targeted therapies in dermatology: a systematic review and analysis. , 2020, Journal of the American Academy of Dermatology.

[10]  Camille M. Moore,et al.  Airspace Macrophages and Monocytes Exist in Transcriptionally Distinct Subsets in Healthy Adults. , 2020, American journal of respiratory and critical care medicine.

[11]  R. Sinclair,et al.  Tofacitinib for cutaneous and pulmonary sarcoidosis: a case series. , 2020, Journal of the American Academy of Dermatology.

[12]  M. Judson.  Causes of Poor Medication Adherence in Sarcoidosis: Poor Patient-Doctor Communication and Suboptimal Drug Regimens. , 2020, Chest.

[13]  S. Birring,et al.  Delphi consensus recommendations for a treatment algorithm in pulmonary sarcoidosis , 2020, European Respiratory Review.

[14]  Mirjana Efremova,et al.  CellPhoneDB: inferring cell–cell communication from combined expression of multi-subunit ligand–receptor complexes , 2020, Nature Protocols.

[15]  E. Miller,et al.  Treatment of Multiorgan Sarcoidosis With Tofacitinib , 2020, ACR open rheumatology.

[16]  B. King,et al.  Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare. , 2020, Journal of the American Academy of Dermatology.

[17]  N. Raine-Fenning,et al.  Results of randomised trial , 2019 .

[18]  J. Grunewald,et al.  Sarcoidosis , 2019, Nature Reviews Disease Primers.

[19]  P. Woodruff,et al.  Serum CXCL11 correlates with pulmonary outcomes and disease burden in sarcoidosis. , 2019, Respiratory medicine.

[20]  T. Lingner,et al.  The IL-1 Pathway Is Hyperactive in Hidradenitis Suppurativa and Contributes to Skin Infiltration and Destruction. , 2019, The Journal of investigative dermatology.

[21]  N. Martis,et al.  Refractory sarcoidosis-like systemic granulomatosis responding to ruxolitinib , 2019, Annals of the rheumatic diseases.

[22]  M. Rosenbach,et al.  Resolution of cutaneous sarcoidosis after Janus kinase inhibitor therapy for concomitant polycythemia vera , 2019, JAAD case reports.

[23]  S. Donnelly,et al.  Tocilizumab in sarcoidosis patients failing steroid sparing therapies and anti-TNF agents , 2019, Respiratory medicine: X.

[24]  W. Sadee,et al.  IL‐13‐regulated Macrophage Polarization during Granuloma Formation in an In Vitro Human Sarcoidosis Model , 2019, American journal of respiratory cell and molecular biology.

[25]  B. King,et al.  Tofacitinib Treatment and Molecular Analysis of Cutaneous Sarcoidosis , 2018, The New England journal of medicine.

[26]  P. Brillet,et al.  Dramatic response of refractory sarcoidosis under ruxolitinib in a patient with associated JAK2-mutated polycythemia , 2018, European Respiratory Journal.

[27]  M. Kool,et al.  Increased T-helper 17.1 cells in sarcoidosis mediastinal lymph nodes , 2018, European Respiratory Journal.

[28]  N. Sato,et al.  CD4 effector T cell differentiation is controlled by IL‐15 that is expressed and presented in trans , 2017, Cytokine.

[29]  L. Cooper,et al.  Joint SNMMI–ASNC expert consensus document on the role of 18F-FDG PET/CT in cardiac sarcoid detection and therapy monitoring , 2017, Journal of Nuclear Cardiology.

[30]  R. Weinberg,et al.  ASNC imaging guidelines for nuclear cardiology procedures , 2017, Journal of Nuclear Cardiology.

[31]  Y. Lussier,et al.  Identification of Jak-STAT signaling involvement in sarcoidosis severity via a novel microRNA-regulated peripheral blood mononuclear cell gene signature , 2017, Scientific Reports.

[32]  Hailing Yang,et al.  Bioinformatics analysis of gene expression profile data to screen key genes involved in pulmonary sarcoidosis. , 2017, Gene.

[33]  B. Becher,et al.  The Cytokine GM-CSF Drives the Inflammatory Signature of CCR2+ Monocytes and Licenses Autoimmunity. , 2015, Immunity.

[34]  A. Lindén,et al.  Higher levels of interleukin IL‐17 and antigen‐specific IL‐17 responses in pulmonary sarcoidosis patients with Löfgren's syndrome , 2014, Clinical and experimental immunology.

[35]  D. Moller.  Negative clinical trials in sarcoidosis: failed therapies or flawed study design? , 2014, European Respiratory Journal.

[36]  G. Raghu,et al.  Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis , 2014, European Respiratory Journal.

[37]  E. Miller,et al.  Quantitative interpretation of FDG PET/CT with myocardial perfusion imaging increases diagnostic information in the evaluation of cardiac sarcoidosis , 2014, Journal of Nuclear Cardiology.

[38]  A. Prasse,et al.  Sarcoidosis , 2014, The Lancet.

[39]  Misha R Agarwal,et al.  Interferon-inducible chemokines reflect severity and progression in sarcoidosis , 2013, Respiratory Research.

[40]  J. Gelfand,et al.  Reliability and convergent validity of the cutaneous sarcoidosis activity and morphology instrument for assessing cutaneous sarcoidosis. , 2013, JAMA dermatology.

[41]  R. Pariser,et al.  A double-blind, randomized, placebo-controlled trial of adalimumab in the treatment of cutaneous sarcoidosis. , 2013, Journal of the American Academy of Dermatology.

[42]  Allison R. Schulman,et al.  18F-FDG PET/CT for the Assessment of Myocardial Sarcoidosis , 2013, Current Cardiology Reports.

[43]  M. Mascelli,et al.  Molecular profiling and gene expression analysis in cutaneous sarcoidosis: the role of interleukin-12, interleukin-23, and the T-helper 17 pathway. , 2012, Journal of the American Academy of Dermatology.

[44]  G. Fadini,et al.  Sarcoidosis is a Th1/Th17 multisystem disorder , 2010, Thorax.

[45]  B. Preston,et al.  Case Series , 2010, Toxicologic pathology.

[46]  Justine R. Smith,et al.  Hypothesis: sarcoidosis is a STAT1-mediated disease. , 2009, Clinical Immunology.

[47]  R. Wahl,et al.  From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors , 2009, Journal of Nuclear Medicine.

[48]  D. Lackland,et al.  The treatment of lupus pernio: results of 116 treatment courses in 54 patients. , 2009, Chest.

[49]  D. Koller,et al.  The Immunological Genome Project: networks of gene expression in immune cells , 2008, Nature Immunology.

[50]  G. Raghu,et al.  Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial , 2008, European Respiratory Journal.

[51]  R. D. du Bois,et al.  Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. , 2006, American journal of respiratory and critical care medicine.

[52]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[53]  T. Karayel,et al.  Cutaneous involvement in sarcoidosis: analysis of the features in 170 patients. , 2003, Respiratory medicine.

[54]  A. Pforte,et al.  Increased interleukin-13 expression in patients with sarcoidosis , 2003, Thorax.

[55]  Makoto Kawashima,et al.  The Japanese Version of Skindex‐16: A Brief Quality‐of‐Life Measure for Patients with Skin Diseases , 2002, The Journal of dermatology.

[56]  M. Chren,et al.  Measurement properties of skindex-16: A brief quality-of-life measure for patients with skin diseases , 2001, Journal of cutaneous medicine and surgery.

[57]  J. Flynn,et al.  An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection , 1993, The Journal of experimental medicine.

[58]  P. Haslam,et al.  Increased levels of serum interferon-gamma in pulmonary sarcoidosis and relationship with response to corticosteroid therapy. , 1991, The American review of respiratory disease.

[59]  R. Crystal,et al.  Gamma interferon is spontaneously released by alveolar macrophages and lung T lymphocytes in patients with pulmonary sarcoidosis. , 1985, The Journal of clinical investigation.

[60]  C. Nathan,et al.  Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity , 1983, The Journal of experimental medicine.